Open Label Trial of INCB07839 to Determine Effect and Safety of INCB007839 Plus Trastuzumab in HER2 Positive Metastatic Breast Cancer
This is a single arm, modified dose escalation, open label trial with the objectives of: (1) Determining a safe optimal dose of INCB007839 in combination with trastuzumab and docetaxel (2) Determining clinical efficacy and safety of INCB007839 in combination with trastuzumab and docetaxel.
Breast Cancer
DRUG: INCB007839|DRUG: INCB007839|DRUG: INCB007839|DRUG: INCB007839|DRUG: trastuzumab|DRUG: Docetaxel
Overall response rate (complete + partial response) using RECIST (Response Evaluation Criteria in Solid Tumor) criteria, Day 1 of each completed subsequent 21-day treatment cycle and the End of Study Visit.
To determine the plasma pharmacokinetic (PK) profile of INCB007839 and trastuzumab when given in combination, For Cycle 1, PK samples to be collected on Day 8 and Day 15 at pre-dose the morning dose of INCB007839. For Cycles 2, 3 and 4, PK will be collected as a single sample, obtained at pre-dose, on Day 1. PK samples will not be collected at Cycle 5 or later.

o. For Cycle 1, PD samples to be collected at time of screening and at pre-dose on Day 1, Day, Monthly
This is a single arm, modified dose escalation, open label trial with the objectives of: (1) Determining a safe optimal dose of INCB007839 in combination with trastuzumab and docetaxel (2) Determining clinical efficacy and safety of INCB007839 in combination with trastuzumab and docetaxel.